Conclusions
PD
With the above methodology, we have identified a broad range of outcome measures which can be potentially included in disease-modifying PD trials, and make recommendations for their inclusion as core, supplementary (for specific arms) and exploratory measures in the EJS ACT-PD MAMS initiative. For other MAMS initiatives, this review aims to serve as a resource from which to select the desired outcome measures according to the requirements of the study (e.g., population, mechanism of action of the intervention, etc.). We also provide a framework for future update of the evidence on outcome measures in disease-modifying PD trials.